Our Mission
Addressing delirium in acute care hospitals is a critical issue, yet there are no existing products for its prevention and detection. DELISPECT is pioneering the first medical device in Japan designed to prevent and detect delirium. Our goal is to enhance patient quality of life, reduce the workload of nurses, and improve the profitability of medical institutions, ultimately tackling the healthcare challenges posed by our super-aging society.
What is Delirium ?
Delirium is a temporary brain dysfunction characterized by cognitive decline and psychomotor agitation. It can lead to decreased physical function and trigger the onset of dementia, resulting in increased caregiving demands and facility admissions. This makes delirium a significant societal issue in acute care settings. Patients experiencing delirium often become hyperactive at night, adding to the workload of healthcare staff. Currently, a shortage of delirium specialists means prevention is not adequately addressed, leading to inefficient management and substantial exhaustion among medical professionals.
News
2021.12.21 We were honored to receive the runner-up award at the BRAVE2021 event by Beyond Next Ventures.
2022.3.7 We were selected for the FY2022 “Medical Device Development Promotion Project” grant by the Japan Agency for Medical Research and Development (AMED).
2022.7.4 We were selected for the second phase of the “National Cancer Center (NCC) Venture Incubation Program,” a program aimed at supporting venture companies dedicated to the practical application of innovative medical technologies. This program is hosted by the National Cancer Center Japan, UTokyo Innovation Platform (UTokyo IPC), and Beyond Next Ventures.